Effective July 27, 2017, Nasonex will be reclassified from preferred to non-preferred. Fluticasone nasal will be the only preferred intranasal corticosteroid for allergic rhinitis. Patients requiring Nasonex on or after July 27, 2017 will require a prior authorization.
Prior authorization forms can be found here:
https://www.navitus.com/texas-medicaid-starchip/prior-authorization-forms.aspx
Questions? Please contact Navitus at 1-877-908-6023.
Date: June 8, 2023 Attention: All Providers Texas Children’s Health Plan (TCHP) would like to notify providers that the timely filing deadline... read more
Date: August 8, 2022 Attention: All Providers Effective Date: June 17, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly... read more
Date: September 14, 2022 Attention: All Providers Effective Date: July 28, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider... read more
Quest Diagnostics is the exclusive contracted lab for TCHP. For OB providers, all genetic testing requires prior authorization. Link to all... read more
Date: July 7, 2022 Attention: All Providers HCPCS Codes from TMHP as of May 2022 Providers should monitor the Texas Children’s Health Plan... read more
Date: March 27, 2024 Attention: STAR Kids Providers/Consumer Directed Services employers and FMSA Providers Call to action: Texas Children’s Health Plan (TCHP)... read more
Date: March 24, 2021 Attention: All Providers Effective Date: March 1, 2021 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal... read more
Date: June 11, 2021 Attention: Primary Care Providers, Emergency Care Providers, and others involved or interested in HIV prevention and care Webinar... read more
Date: April 2, 2024 Attention: All Providers Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that our... read more
Effective for dates of service on or after September 1, 2017, physical therapy (PT), occupational therapy (OT) and speech therapy... read more
Leave a Reply
You must be logged in to post a comment.